Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

RiboGene's PCP Drug Approaches Clinical Trials




 

Business Wire (06/12/95)

On Monday, RiboGene, Inc. announced that it will proceed with human clinical trials of RG-201, the company's leading anti- fungal compound for the treatment of Pneumocystis carinii pneumonia. PCP is one of the most common opportunistic infections to affect AIDS patients. The drug is the company's first clinical trial candidate under its partnership with the University of North Carolina (UNC), Pharmo-Eco Laboratories, and Dr. Richard Tidwell of UNC, who is a consultant to RiboGene.



 


Copyright © 1995 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 13, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.